CINCINNATI, OH, Feb. 13, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the “Company” or “Callitas”) a diversified clinical-stage pharmaceutical development, OTC consumer healthcare and proprietary cannabis delivery development and marketing company, announced today that it has signed a product development and manufacturing agreement with LifeStyles.
“At LifeStyles, our mission is to spark billions of joyful moments every day, regardless of gender, age, race, religion and sexuality. We are committed to continuous innovation that can help people enjoy healthier and more fulfilling intimacy, and the collaboration with Callitas is an important part of this commitment,” says Jeyan Heper, CEO at LifeStyles.
The two companies signed a letter of intent in August of 2018 to develop and supply unique finished goods for retail sale. This finalized commercial agreement allows for further research and development and product realization, coming later this quarter.
“We’ve been impressed with LifeStyles and their model of business and leadership team,” said James M. Thompson, President and CEO. “Callitas looks forward to our ongoing relationship, one that will be mutually beneficial for both companies’ futures.”
Callitas, which focuses on developing innovative technologies for sexual health and wellness, among others, will be developing sexual wellness products for LifeStyles, with the first item launching in March 2019.
“Callitas is looking forward to continuing our relationship with LifeStyles to bring novel products to market,” said Joshua Maurice, Director of Sales and Marketing for Callitas. “LifeStyles has worldwide brand recognition and partnering with them will be a huge opportunity for our company to expand our innovative ideas.”
About LifeStyles: LifeStyles has a history dating back to 1905 when Eric Ansell first started making condoms in Richmond Australia. Today LifeStyles is a Global leader in the sexual wellness sector, comprising a broad range of condom, personal lubricant and other related products. LifeStyles is the world’s #2 condom company with leading latex brands such as LifeStyles®, Jissbon®, Manix®, Unimil®, Blowtex® and others, as well as the fast-growing, highly-innovative non-latex condom brand SKYN®. LifeStyles Healthcare was created on September 1, 2017 when the consortium of Humanwell Healthcare & CITIC Capital private equity purchased the Sexual Wellness division from Ansell.
About Callitas Health: Formed in early 2015, Callitas Health Inc. is a diversified clinical-stage pharmaceutical development, OTC consumer healthcare and proprietary cannabis delivery development and marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive(www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.
Contacts:
Callitas Health:
James Thompson, CEO, o
Callitas Investor Relations
Phone: +1 (859) 868-3131
TraDigitalIR:
Investor Relations – Kevin McGrath, Managing Director
Phone: +1 (646) 418-7002
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body. Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.
